Lantheus Holdings

General Information
Business:

We are a global leader in developing, manufacturing, selling and distributing innovative diagnostic medical imaging agents and products that assist clinicians in the diagnosis of cardiovascular and other diseases. Our agents are routinely used to diagnose coronary artery disease, congestive heart failure, stroke, peripheral vascular disease and other diseases. Clinicians use our imaging agents and products across a range of imaging modalities, including nuclear imaging, echocardiography and MRI. We believe that the resulting improved diagnostic information enables healthcare providers to better detect and characterize, or rule out, disease, potentially achieving improved patient outcomes, reducing patient risk and limiting overall costs for payers and the entire healthcare system.

Industry: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Employees: 521
Founded: 1956
Contact Information
Address 331 Treble Cove Road, North Billerica, MA 01862, US
Phone Number 978-671-8001
Web Address http://www.lantheus.com
View Prospectus: Lantheus Holdings
Financial Information
Market Cap $176.2mil
Revenues $303.1 mil (last 12 months)
Net Income $-3.2 mil (last 12 months)
IPO Profile
Symbol LNTH
Exchange NASDAQ
Shares (millions): 10.8
Price range $6.00 - $6.00
Est. $ Volume $65.0 mil
Manager / Joint Managers Credit Suisse/ Jefferies/ RBC Capital Markets/ Wells Fargo Securities
CO-Managers Baird
Expected To Trade: 6/25/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change